id doaj-d4dcdecbbcf04a1fa1ec9b6d81c363e2
record_format Article
spelling doaj-d4dcdecbbcf04a1fa1ec9b6d81c363e22021-07-28T14:04:07ZrusOOO “Vashe Tsifrovoe Izdatelstvo”Ведомости Научного центра экспертизы средств медицинского применения1991-29192619-11722018-02-0103606453Pharmacoeconomics of spastic cerebral palsyR. I. Yagudina0A. U. Kulikov1N. I. Korolyova2D. T. Ugrekhelidze3Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian FederationFederal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health of the Russian FederationI.M. Sechenov First Moscow State Medical UniversityCerebral palsy (CP) is one of the most widespread and socially significant neurological diseases that affect both various aspects of physical and psychoverbal development of children since birth and stages of their personal development and adaptation in society. Over the last years there has been an increase in the number of children with disabilities in Russia, and it should be noted that CP ranks first among neurological disabilities in children. Given the lifetime course of this disease, CP acquires a huge medical and socioeconomic relevance. In particular, it is necessary to use the most efficient medical technologies (from the point of view of both efficacy, safety and costs). Pharmacoeconomic analysis is the most suitable tool for solving these tasks. However, when performing pharmacoeconomic analysis in the field of cerebral palsy, as well as in any other disease area, it is obligatory to take into account certain peculiarities at the planning and implementation stages. The authors of the article have identified specific features of pharmacoeconomic analysis methods based on assessment of health technologies related to cerebral palsy.https://www.vedomostincesmp.ru/jour/article/view/55спастичностьдетский церебральный параличфармакоэкономический анализмоделированиеанализ затратанализ эффективностикритерии эффективностианализ «влияния на бюджет»оценка технологий здравоохраненияspasticitycerebral palsypharmacoeconomic analysismodelingcost analysisefficiency analysisefficiency criteriabudget impact analysishealth technologies assessment
collection DOAJ
language Russian
format Article
sources DOAJ
author R. I. Yagudina
A. U. Kulikov
N. I. Korolyova
D. T. Ugrekhelidze
spellingShingle R. I. Yagudina
A. U. Kulikov
N. I. Korolyova
D. T. Ugrekhelidze
Pharmacoeconomics of spastic cerebral palsy
Ведомости Научного центра экспертизы средств медицинского применения
спастичность
детский церебральный паралич
фармакоэкономический анализ
моделирование
анализ затрат
анализ эффективности
критерии эффективности
анализ «влияния на бюджет»
оценка технологий здравоохранения
spasticity
cerebral palsy
pharmacoeconomic analysis
modeling
cost analysis
efficiency analysis
efficiency criteria
budget impact analysis
health technologies assessment
author_facet R. I. Yagudina
A. U. Kulikov
N. I. Korolyova
D. T. Ugrekhelidze
author_sort R. I. Yagudina
title Pharmacoeconomics of spastic cerebral palsy
title_short Pharmacoeconomics of spastic cerebral palsy
title_full Pharmacoeconomics of spastic cerebral palsy
title_fullStr Pharmacoeconomics of spastic cerebral palsy
title_full_unstemmed Pharmacoeconomics of spastic cerebral palsy
title_sort pharmacoeconomics of spastic cerebral palsy
publisher OOO “Vashe Tsifrovoe Izdatelstvo”
series Ведомости Научного центра экспертизы средств медицинского применения
issn 1991-2919
2619-1172
publishDate 2018-02-01
description Cerebral palsy (CP) is one of the most widespread and socially significant neurological diseases that affect both various aspects of physical and psychoverbal development of children since birth and stages of their personal development and adaptation in society. Over the last years there has been an increase in the number of children with disabilities in Russia, and it should be noted that CP ranks first among neurological disabilities in children. Given the lifetime course of this disease, CP acquires a huge medical and socioeconomic relevance. In particular, it is necessary to use the most efficient medical technologies (from the point of view of both efficacy, safety and costs). Pharmacoeconomic analysis is the most suitable tool for solving these tasks. However, when performing pharmacoeconomic analysis in the field of cerebral palsy, as well as in any other disease area, it is obligatory to take into account certain peculiarities at the planning and implementation stages. The authors of the article have identified specific features of pharmacoeconomic analysis methods based on assessment of health technologies related to cerebral palsy.
topic спастичность
детский церебральный паралич
фармакоэкономический анализ
моделирование
анализ затрат
анализ эффективности
критерии эффективности
анализ «влияния на бюджет»
оценка технологий здравоохранения
spasticity
cerebral palsy
pharmacoeconomic analysis
modeling
cost analysis
efficiency analysis
efficiency criteria
budget impact analysis
health technologies assessment
url https://www.vedomostincesmp.ru/jour/article/view/55
work_keys_str_mv AT riyagudina pharmacoeconomicsofspasticcerebralpalsy
AT aukulikov pharmacoeconomicsofspasticcerebralpalsy
AT nikorolyova pharmacoeconomicsofspasticcerebralpalsy
AT dtugrekhelidze pharmacoeconomicsofspasticcerebralpalsy
_version_ 1721268638483218432